rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2023-639-649rsp-3469Research ArticleПЕРЕДОВАЯLEADING ARTICLEПроблемы системных заболеваний соединительной ткани детского возраста в исторической перспективеProblems of systemic connective tissue diseases of childhood in historical perspectivehttps://orcid.org/0000-0002-0513-6826КаледаМ. И.KaledaM. I.

Каледа Мария Игоревна.

115522, Москва, Каширское шоссе, 34а

Maria I. Kaleda.

115522, Moscow, Kashirskoye Highway, 34A

kaleda-mi@yandex.ruhttps://orcid.org/0000-0003-1842-0348НикишинаИ. П.NikishinaI. P.

115522, Москва, Каширское шоссе, 34а

Irina P. Nikishina.

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202330122023616639649Copyright © Каледа М.И., Никишина И.П., 20242024Каледа М.И., Никишина И.П.Kaleda M.I., Nikishina I.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3469

Актуальность изучения системных заболеваний соединительной ткани с ювенильным началом для современной медицины определяется тенденцией к их росту в популяции, трудностью ранней диагностики, быстрым развитием инвалидности и неблагоприятным жизненным прогнозом. В статье представлены основные достижения в изучении этой группы заболеваний у детей с акцентом на наиболее значимые с практической точки зрения вопросы, связанные с диагностикой, классификацией, особенностями клинической картины и современными подходами к терапии.

The relevance of study systemic connective tissue diseases with juvenile onset for modern medicine is determined by the trend towards their growth in the population, the difficulty of early diagnosis, the rapid development of disability and a poor life prognosis. The article presents the main achievements in the study of this group of diseases in children, with an emphasis on the most significant issues from a practical point of view related to diagnosis, classification, clinical features and modern approaches to treatment.

системные заболевания соединительной тканисистемная красная волчанка с ювенильным началомсистемный склероз с ювенильным началомювенильный дерматомиозитдетский возрастsystemic connective tissue diseasessystemic lupus erythematosus with juvenile onsetsystemic sclerosis with juvenile onsetjuvenile dermatomyositischildhoodСтатья подготовлена в рамках фундаментального научного исследования по теме «Выявление клинических фенотипов и прогнозирование вариантов течения аутоиммунных и аутовоспалительных ревматических заболеваний детского возраста» FURS-2022-0001, регистрационный номер в ЕГИСУ 1021051302580-4.ReferencesTarvin SE, O’Neil KM, Systemic lupus erythematosus, Sjögren syndrome, and mixed connective tissue disease in children and adolescents. Pediatr Clin North Am. 2018;65(4):711-737. doi: 10.1016/j.pcl.2018.04.001Tarvin SE, O’Neil KM, Systemic lupus erythematosus, Sjögren syndrome, and mixed connective tissue disease in children and adolescents. Pediatr Clin North Am. 2018;65(4):711-737. doi: 10.1016/j.pcl.2018.04.001Klemperer P, Pollack AD, Baehr G. Diffuse collagen disease. Arch Path. 1941;32:569-591.Klemperer P, Pollack AD, Baehr G. Diffuse collagen disease. Arch Path. 1941;32:569-591.Сигидин ЯА, Иванова ММ, Гусева НГ. Диффузные болезни соединительной ткани (системные ревматические заболевания). Руководство для врачей. М.:Медицина;1994.Sigidin YaA, Ivanova MM, Guseva NG. Diffuse connective tissue diseases (systemic rheumatic diseases): Guidelines for physicians. Moscow:Meditsina;1994 (In Russ.).Лыскина Г.А. Проблемы системных заболеваний соединительной ткани у детей. Педиатрия. Журнал им. Г.Н. Сперанского. 2004;2:46-52.Lyskina GA. Problems of systemic connective tissue diseases in children. Journal “Pediatria” named after G.N. Speransky. 2004;2:46-52 (In Russ.)].McGonagle D, Aziz A, Dickie LJ, McDermott MF. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res. 2009;65(5 Pt 2):38R-45R. doi: 10.1203/PDR.0b013e31819dbd0aMcGonagle D, Aziz A, Dickie LJ, McDermott MF. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res. 2009;65(5 Pt 2):38R-45R. doi: 10.1203/PDR.0b013e31819dbd0aCui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: Recent progress from GWAS. J Autoimmun. 2013;41:25-33. doi: 10.1016/j.jaut.2013.01.008Cui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: Recent progress from GWAS. J Autoimmun. 2013;41:25-33. doi: 10.1016/j.jaut.2013.01.008Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019;209:108274. doi: 10.1016/j.clim.2019.108274Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019;209:108274. doi: 10.1016/j.clim.2019.108274Alexander T, Hedrich CM. Systemic lupus erythematosus – Are children miniature adults? Clin Immunol. 2022;234:108907. doi: 10.1016/j.clim.2021.108907Alexander T, Hedrich CM. Systemic lupus erythematosus – Are children miniature adults? Clin Immunol. 2022;234:108907. doi: 10.1016/j.clim.2021.108907Асеева ЕА, Лила АМ, Соловьев СК, Насонов ЕЛ, Глухова СИ. Клинико-иммунологические фенотипы системной красной волчанки, выделенные на основании кластерного анализа данных 400 пациентов ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой». Современная ревматология. 2022;16(5):13-21. doi: 10.14412/1996-7012-2022-5-13-21Aseeva EA, Lila AM, Soloviev SK, Nasonov EL, Glukhova SI. Clinical and immunological phenotypes of systemic lupus erythematosus, identified based on cluster analysis of data from 400 patients from V.A. Nasonova Research Institute of Rheumatology. Modern Rheumatology Journal. 2022;16(5):13-21 (In Russ.). doi: 10.14412/1996-7012-2022-5-13-21Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain RJEM, et al. Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(2):290-301. doi: 10.1002/art.40697Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain RJEM, et al. Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(2):290-301. doi: 10.1002/art.40697Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am. 2012;59(2):345-364. doi: 10.1016/j.pcl.2012.03.007Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am. 2012;59(2):345-364. doi: 10.1016/j.pcl.2012.03.007Huang JL, Yao TC, See LC. Prevalence of pediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: A nation-wide prospective population-based study in Taiwan. Clin Exp Rheumatol. 2004;22:776-780.Huang JL, Yao TC, See LC. Prevalence of pediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: A nation-wide prospective population-based study in Taiwan. Clin Exp Rheumatol. 2004;22:776-780.Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) – Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017;31(4):488-504. doi: 10.1016/j.berh.2018.02.001Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) – Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017;31(4):488-504. doi: 10.1016/j.berh.2018.02.001Ardoin SP, Daly RP, Merzoug L, Tse K, Ardalan K, Arkin L, et al.; Childhood Arthritis and Rheumatology Research Alliance and Lupus Foundation of America. Research priorities in childhood -onset lupus: Results of a multidisciplinary prioritization exercise. Pediatr Rheumatol Online J. 2019;17(1):32. doi: 10.1186/s12969-019-0327-4Ardoin SP, Daly RP, Merzoug L, Tse K, Ardalan K, Arkin L, et al.; Childhood Arthritis and Rheumatology Research Alliance and Lupus Foundation of America. Research priorities in childhood -onset lupus: Results of a multidisciplinary prioritization exercise. Pediatr Rheumatol Online J. 2019;17(1):32. doi: 10.1186/s12969-019-0327-4Appenzeller S, Pereira DR, Julio PR, Reis F, Rittner L, Marini R. Neuropsychiatric manifestations in childhood-onset systemic lupus erythematosus. Lancet Child Adolesc Health. 2022;6(8):571-581. doi: 10.1016/S2352-4642(22)00157-2Appenzeller S, Pereira DR, Julio PR, Reis F, Rittner L, Marini R. Neuropsychiatric manifestations in childhood-onset systemic lupus erythematosus. Lancet Child Adolesc Health. 2022;6(8):571-581. doi: 10.1016/S2352-4642(22)00157-2Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023;10(1):5. doi: 10.1186/s40348-023-00161-7Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023;10(1):5. doi: 10.1186/s40348-023-00161-7Каледа МИ, Никишина ИП, Глухова СИ, Степаненко НЮ. Нейропсихические нарушения при ювенильном дебюте системной красной волчанки: результаты ретроспективного исследования. Научно-практическая ревматология. 2020;58(2):171-177. doi: 10.14412/1995-4484-2020-171-177Kaleda MI, Nikishina IP, Glukhova SI, Stepanenko NYu. Neuropsychiatric disorders in juvenile-onset systemic lupus erythematosus: Results from a retrospective study. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(2):171-177 (In Russ.). doi: 10.14412/1995-4484-2020-171-177Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021;11(7):928. doi: 10.3390/biom11070928Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021;11(7):928. doi: 10.3390/biom11070928Caielli S, Wan Z, Pascual V. Systemic lupus erythematosus pathogenesis: Interferon and beyond. Annu Rev Immunol. 2023;41:533-560. doi: 10.1146/annurev-immunol-101921-042422Caielli S, Wan Z, Pascual V. Systemic lupus erythematosus pathogenesis: Interferon and beyond. Annu Rev Immunol. 2023;41:533-560. doi: 10.1146/annurev-immunol-101921-042422Li H, Wang T, Li B, Huang T, Hai Y, Huang C, et al. Bioinformatic analysis of immune-related transcriptome affected by IFIT1 gene in childhood systemic lupus erythematosus. Transl Pediatr. 2023;12(8):1517-1526. doi: 10.21037/tp-23-365Li H, Wang T, Li B, Huang T, Hai Y, Huang C, et al. Bioinformatic analysis of immune-related transcriptome affected by IFIT1 gene in childhood systemic lupus erythematosus. Transl Pediatr. 2023;12(8):1517-1526. doi: 10.21037/tp-23-365Sestan M, Kifer N, Arsov T, Cook M, Ellyard J, Vinuesa CG, et al. The role of genetic risk factors in pathogenesis of childhoodonset systemic lupus erythematosus. Curr Issues Mol Biol. 2023;45(7):5981-6002. doi: 10.3390/cimb45070378Sestan M, Kifer N, Arsov T, Cook M, Ellyard J, Vinuesa CG, et al. The role of genetic risk factors in pathogenesis of childhoodonset systemic lupus erythematosus. Curr Issues Mol Biol. 2023;45(7):5981-6002. doi: 10.3390/cimb45070378Massias JS, Smith EMD, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus. 2020;29(5):474-481. doi: 10.1177/0961203320909156Massias JS, Smith EMD, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus. 2020;29(5):474-481. doi: 10.1177/0961203320909156Massias JS, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory phenotypes in juvenile-onset systemic lupus erythematosus across ethnicities in the UK. Lupus. 2021;30(4):597-607. doi: 10.1177/0961203320984251Massias JS, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory phenotypes in juvenile-onset systemic lupus erythematosus across ethnicities in the UK. Lupus. 2021;30(4):597-607. doi: 10.1177/0961203320984251Lythgoe H, Lj M, Hedrich CM, Aringer M. Classification of systemic lupus erythematosus in children and adults. Clin Immunol. 2022;234:108898. doi: 10.1016/j.clim.2021.108898Lythgoe H, Lj M, Hedrich CM, Aringer M. Classification of systemic lupus erythematosus in children and adults. Clin Immunol. 2022;234:108898. doi: 10.1016/j.clim.2021.108898Chang LS, Huang PY, Kuo HC, Tu YK, Tseng PT, Liang CS, et al. Diagnostic accuracy of the American College of Rheumatology-1997, the Systemic Lupus International Collaborating Clinics-2012, and the European League Against Rheumatism-2019 criteria for juvenile systemic lupus erythematosus: A systematic review and network meta-analysis. Autoimmun Rev. 2022;21(9):103144. doi: 10.1016/j.autrev.2022.103144Chang LS, Huang PY, Kuo HC, Tu YK, Tseng PT, Liang CS, et al. Diagnostic accuracy of the American College of Rheumatology-1997, the Systemic Lupus International Collaborating Clinics-2012, and the European League Against Rheumatism-2019 criteria for juvenile systemic lupus erythematosus: A systematic review and network meta-analysis. Autoimmun Rev. 2022;21(9):103144. doi: 10.1016/j.autrev.2022.103144Falcini F, Nacci F. Systemic lupus erythematosus in the young: The importance of a transition clinic. Lupus. 2007;16(8):613-617. doi: 10.1177/0961203307078973Falcini F, Nacci F. Systemic lupus erythematosus in the young: The importance of a transition clinic. Lupus. 2007;16(8):613-617. doi: 10.1177/0961203307078973Alperin JM, Ortiz-Fernández L, Sawalha AH. Monogenic lupus: A developing paradigm of disease. Front Immunol. 2018;9:2496. doi: 10.3389/fimmu.2018.02496Alperin JM, Ortiz-Fernández L, Sawalha AH. Monogenic lupus: A developing paradigm of disease. Front Immunol. 2018;9:2496. doi: 10.3389/fimmu.2018.02496Harley ITW, Sawalha AH. Systemic lupus erythematosus as a genetic disease. Clin Immunol. 2022;236:108953. doi: 10.1016/j.clim.2022.108953Harley ITW, Sawalha AH. Systemic lupus erythematosus as a genetic disease. Clin Immunol. 2022;236:108953. doi: 10.1016/j.clim.2022.108953Demirkaya E, Sahin S, Romano M, Zhou Q, Aksentijevich I. New horizons in the genetic etiology of systemic lupus erythematosus and lupus-like disease: Monogenic lupus and beyond. J Clin Med. 2020;9(3):712. doi: 10.3390/jcm9030712Demirkaya E, Sahin S, Romano M, Zhou Q, Aksentijevich I. New horizons in the genetic etiology of systemic lupus erythematosus and lupus-like disease: Monogenic lupus and beyond. J Clin Med. 2020;9(3):712. doi: 10.3390/jcm9030712Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian interferonopathies: Comparison of CANDLE, SAVI with AGS, monogenic lupus. J Mol Med (Berl). 2016;94(10):1111-1127. doi: 10.1007/s00109-016-1465-5Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian interferonopathies: Comparison of CANDLE, SAVI with AGS, monogenic lupus. J Mol Med (Berl). 2016;94(10):1111-1127. doi: 10.1007/s00109-016-1465-5Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020;146(5):925-937. doi: 10.1016/j.jaci.2020.08.017Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020;146(5):925-937. doi: 10.1016/j.jaci.2020.08.017Sandling JK, Pucholt P, Hultin Rosenberg L, Farias FHG, Kozyrev SV, Eloranta ML, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis. 2021;80(1):109-117. doi: 10.1136/annrheumdis-2020-218636Sandling JK, Pucholt P, Hultin Rosenberg L, Farias FHG, Kozyrev SV, Eloranta ML, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis. 2021;80(1):109-117. doi: 10.1136/annrheumdis-2020-218636Al-Mayouf SM, Alreefi HA, Alsinan TA, AlSalmi G, AlRowais A, Al-Herz W, et al. Lupus manifestations in children with primary immunodeficiency diseases: Comprehensive phenotypic and genetic features and outcome. Mod Rheumatol. 2021;31(6):1171-1178. doi: 10.1080/14397595.2021.1886627Al-Mayouf SM, Alreefi HA, Alsinan TA, AlSalmi G, AlRowais A, Al-Herz W, et al. Lupus manifestations in children with primary immunodeficiency diseases: Comprehensive phenotypic and genetic features and outcome. Mod Rheumatol. 2021;31(6):1171-1178. doi: 10.1080/14397595.2021.1886627Chan SCW, Lau CS. Systemic lupus erythematosus and immunodeficiency. Rheumatol Immunol Res. 2021;2(3):131-138. doi: 10.2478/rir-2021-0019Chan SCW, Lau CS. Systemic lupus erythematosus and immunodeficiency. Rheumatol Immunol Res. 2021;2(3):131-138. doi: 10.2478/rir-2021-0019Ozturk K, Caglayan S, Tanatar A, Baglan E, Yener Otar G, Kavrul Kayaalp G, et al.; PeRA-Research Group. Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus. 2021;30(13):2144-2150. doi: 10.1177/09612033211054399Ozturk K, Caglayan S, Tanatar A, Baglan E, Yener Otar G, Kavrul Kayaalp G, et al.; PeRA-Research Group. Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus. 2021;30(13):2144-2150. doi: 10.1177/09612033211054399Nakorn K, Piyaphanee N, Sukharomana M, Pinpatanapong R, Charuvanij S. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus. Clin Rheumatol. 2023;42(6):1655-1664. doi: 10.1007/s10067-023-06533-8Nakorn K, Piyaphanee N, Sukharomana M, Pinpatanapong R, Charuvanij S. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus. Clin Rheumatol. 2023;42(6):1655-1664. doi: 10.1007/s10067-023-06533-8Groot N, de Graeff N, Avcin T, Bader-Meunier B, Brogan P, Dolezalova P, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: The SHARE initiative. Ann Rheum Dis. 2017;76(11):1788-1796. doi: 10.1136/annrheumdis-2016-210960Groot N, de Graeff N, Avcin T, Bader-Meunier B, Brogan P, Dolezalova P, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: The SHARE initiative. Ann Rheum Dis. 2017;76(11):1788-1796. doi: 10.1136/annrheumdis-2016-210960Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2989-2996. doi: 10.1002/art.22048Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2989-2996. doi: 10.1002/art.22048Blamires J, Foster M, Napier S, Dickinson A. Experiences and perspectives of children and young people living with childhood -onset systemic lupus erythematosus – An integrative review. Children (Basel). 2023;10(6):1006. doi: 10.3390/children10061006Blamires J, Foster M, Napier S, Dickinson A. Experiences and perspectives of children and young people living with childhood -onset systemic lupus erythematosus – An integrative review. Children (Basel). 2023;10(6):1006. doi: 10.3390/children10061006Zulian F. Scleroderma in children. Best Pract Res Clin Rheumatol. 2017;31(4):576-595. doi: 10.1016/j.berh.2018.02.004Zulian F. Scleroderma in children. Best Pract Res Clin Rheumatol. 2017;31(4):576-595. doi: 10.1016/j.berh.2018.02.004Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken). 2010;62(2):213-218. doi: 10.1002/acr.20070Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken). 2010;62(2):213-218. doi: 10.1002/acr.20070Beukelman T, Xie F, Foeldvari I. Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States. J Scleroderma Relat Disord. 2018;3(2):189-190. doi: 10.1177/2397198318763701Beukelman T, Xie F, Foeldvari I. Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States. J Scleroderma Relat Disord. 2018;3(2):189-190. doi: 10.1177/2397198318763701Martini G, Vittadello F, Kasapçopur O, Magni Manzoni S, Corona F, Duarte-Salazar C, et al.; Juvenile Scleroderma Working Group of Paediatric Rheumatology European Society (PRES). Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford). 2009;48(2):119-222. doi: 10.1093/rheumatology/ken388Martini G, Vittadello F, Kasapçopur O, Magni Manzoni S, Corona F, Duarte-Salazar C, et al.; Juvenile Scleroderma Working Group of Paediatric Rheumatology European Society (PRES). Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford). 2009;48(2):119-222. doi: 10.1093/rheumatology/ken388Valeur NS, Stevens AM, Ferguson MR, Effmann EL, Iyer RS. Multimodality thoracic imaging of juvenile systemic sclerosis: Emphasis on clinical correlation and high-resolution CT of pulmonary fibrosis. AJR Am J Roentgenol. 2015;204(2):408-422. doi: 10.2214/AJR.14.12461Valeur NS, Stevens AM, Ferguson MR, Effmann EL, Iyer RS. Multimodality thoracic imaging of juvenile systemic sclerosis: Emphasis on clinical correlation and high-resolution CT of pulmonary fibrosis. AJR Am J Roentgenol. 2015;204(2):408-422. doi: 10.2214/AJR.14.12461Li SC. Scleroderma in children and adolescents: Localized scleroderma and systemic sclerosis. Pediatr Clin North Am. 2018;65(4):757-781. doi: 10.1016/j.pcl.2018.04.002Li SC. Scleroderma in children and adolescents: Localized scleroderma and systemic sclerosis. Pediatr Clin North Am. 2018;65(4):757-781. doi: 10.1016/j.pcl.2018.04.002Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV Jr, et al. Childhood onset systemic sclerosis: Classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006;33(5):1004-1013.Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV Jr, et al. Childhood onset systemic sclerosis: Classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006;33(5):1004-1013.Rutkowska-Sak L, Gietka P, Gazda A, Kołodziejczyk B. Juvenile systemic sclerosis – observations of one clinical centre. Reumatologia. 2021;59(6):367-372. doi: 10.5114/reum.2021.112350Rutkowska-Sak L, Gietka P, Gazda A, Kołodziejczyk B. Juvenile systemic sclerosis – observations of one clinical centre. Reumatologia. 2021;59(6):367-372. doi: 10.5114/reum.2021.112350Céspedes-Cruz AI, Carranza-Muleiro RA, López-Rojas EL, Cruz-Domínguez MP, Espinosa-Gan H, Ramírez-Pérez J, et al. Pulmonary involvement in patients with juvenile systemic sclerosis. Bol Med Hosp Infant Mex. 2021;78(5):385-394. doi: 10.24875/BMHIM.20000301Céspedes-Cruz AI, Carranza-Muleiro RA, López-Rojas EL, Cruz-Domínguez MP, Espinosa-Gan H, Ramírez-Pérez J, et al. Pulmonary involvement in patients with juvenile systemic sclerosis. Bol Med Hosp Infant Mex. 2021;78(5):385-394. doi: 10.24875/BMHIM.20000301Foeldvari I, Klotsche J, Hinrichs B, Helmus N, Kasapcopur O, Adrovic A, et al. Underdetection of interstitial lung disease in juvenile systemic sclerosis. Arthritis Care Res (Hoboken). 2022;74(3):364-370. doi: 10.1002/acr.24499Foeldvari I, Klotsche J, Hinrichs B, Helmus N, Kasapcopur O, Adrovic A, et al. Underdetection of interstitial lung disease in juvenile systemic sclerosis. Arthritis Care Res (Hoboken). 2022;74(3):364-370. doi: 10.1002/acr.24499Apitz C, Girschick H. Systemic sclerosis-associated pulmonary arterial hypertension in children. Cardiovasc Diagn Ther. 2021;11(4):1137-1143. doi: 10.21037/cdt-20-901Apitz C, Girschick H. Systemic sclerosis-associated pulmonary arterial hypertension in children. Cardiovasc Diagn Ther. 2021;11(4):1137-1143. doi: 10.21037/cdt-20-901Adrovic A, Karatemiz G, Esatoglu SN, Yildiz M, Sahin S, Barut K, et al. Juvenile and adult-onset scleroderma: Different clinical phenotypes. Semin Arthritis Rheum. 2023;60:152197. doi: 10.1016/j.semarthrit.2023.152197Adrovic A, Karatemiz G, Esatoglu SN, Yildiz M, Sahin S, Barut K, et al. Juvenile and adult-onset scleroderma: Different clinical phenotypes. Semin Arthritis Rheum. 2023;60:152197. doi: 10.1016/j.semarthrit.2023.152197Foeldvari I, Klotsche J, Torok KS, Kasapcopur O, Adrovic A, Stanevicha V, et al. Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort. J Scleroderma Relat Disord. 2019;4(1):49-61. doi: 10.1177/2397198318790494Foeldvari I, Klotsche J, Torok KS, Kasapcopur O, Adrovic A, Stanevicha V, et al. Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort. J Scleroderma Relat Disord. 2019;4(1):49-61. doi: 10.1177/2397198318790494Foeldvari I, Klotsche J, Kasapcopur O, Adrovic A, Terreri MT, Sakamoto AP, et al. Gender differences in juvenile systemic sclerosis patients: Results from the international juvenile scleroderma inception cohort. J Scleroderma Relat Disord. 2023;8(2):120-130. doi: 10.1177/23971983221143244Foeldvari I, Klotsche J, Kasapcopur O, Adrovic A, Terreri MT, Sakamoto AP, et al. Gender differences in juvenile systemic sclerosis patients: Results from the international juvenile scleroderma inception cohort. J Scleroderma Relat Disord. 2023;8(2):120-130. doi: 10.1177/23971983221143244Stevens AM, Torok KS, Li SC, Taber SF, Lu TT, Zulian F. Immunopathogenesis of juvenile systemic sclerosis. Front Immunol. 2019;10:1352. doi: 10.3389/fimmu.2019.01352Stevens AM, Torok KS, Li SC, Taber SF, Lu TT, Zulian F. Immunopathogenesis of juvenile systemic sclerosis. Front Immunol. 2019;10:1352. doi: 10.3389/fimmu.2019.01352Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA Jr, Lehman TJ, et al. The Pediatric Rheumatology European Society/ American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 2007;57(2):203-212. doi: 10.1002/art.22551Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA Jr, Lehman TJ, et al. The Pediatric Rheumatology European Society/ American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 2007;57(2):203-212. doi: 10.1002/art.22551van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. doi: 10.1136/annrheumdis-2013-204424van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. doi: 10.1136/annrheumdis-2013-204424Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, et al.; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society. Systemic sclerosis in childhood: Clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971-3978. doi: 10.1002/art.22207Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, et al.; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society. Systemic sclerosis in childhood: Clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971-3978. doi: 10.1002/art.22207Foeldvari I, Culpo R, Sperotto F, Anton J, Avcin T, Baildam E, et al. Consensus-based recommendations for the management of juvenile systemic sclerosis. Rheumatology (Oxford). 2021;60(4):1651-1658. doi: 10.1093/rheumatology/keaa584Foeldvari I, Culpo R, Sperotto F, Anton J, Avcin T, Baildam E, et al. Consensus-based recommendations for the management of juvenile systemic sclerosis. Rheumatology (Oxford). 2021;60(4):1651-1658. doi: 10.1093/rheumatology/keaa584Klotsche J, Torok KS, Kasapcopur O, Adrovic A, Terreri MT, Sakamoto AP, et al. Application and performance of disease activity indices proposed for patients with systemic sclerosis in an international cohort of patients with juvenile systemic sclerosis. J Scleroderma Relat Disord. 2023;8(3):183-191. doi: 10.1177/23971983231164700Klotsche J, Torok KS, Kasapcopur O, Adrovic A, Terreri MT, Sakamoto AP, et al. Application and performance of disease activity indices proposed for patients with systemic sclerosis in an international cohort of patients with juvenile systemic sclerosis. J Scleroderma Relat Disord. 2023;8(3):183-191. doi: 10.1177/23971983231164700Beukelman T, Xie F, Foeldvari I. The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the United States. J Scleroderma Relat Disord. 2019;4(1): 77-78. doi: 10.1177/2397198318798588Beukelman T, Xie F, Foeldvari I. The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the United States. J Scleroderma Relat Disord. 2019;4(1): 77-78. doi: 10.1177/2397198318798588Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, et al.; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9):2873-2881. doi: 10.1002/art.21264Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, et al.; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9):2873-2881. doi: 10.1002/art.21264Papadopoulou C, Chew C, Wilkinson MGL, McCann L, Wedderburn LR. Juvenile idiopathic inflammatory myositis: An update on pathophysiology and clinical care. Nat Rev Rheumatol. 2023;19(6):343-362. doi: 10.1038/s41584-023-00967-9Papadopoulou C, Chew C, Wilkinson MGL, McCann L, Wedderburn LR. Juvenile idiopathic inflammatory myositis: An update on pathophysiology and clinical care. Nat Rev Rheumatol. 2023;19(6):343-362. doi: 10.1038/s41584-023-00967-9Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: A systematic review. Rheumatology (Oxford). 2015;54(1):50-63. doi: 10.1093/rheumatology/keu289Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: A systematic review. Rheumatology (Oxford). 2015;54(1):50-63. doi: 10.1093/rheumatology/keu289Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al.; with the Childhood Myositis Heterogeneity Collaborative Study Group. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(1):25-41. doi: 10.1097/MD.0b013e31827f264dShah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al.; with the Childhood Myositis Heterogeneity Collaborative Study Group. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(1):25-41. doi: 10.1097/MD.0b013e31827f264dRavelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63-72. doi: 10.1002/acr.20015Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63-72. doi: 10.1002/acr.20015Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016;280(1):24-38. doi: 10.1111/joim.12444Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016;280(1):24-38. doi: 10.1111/joim.12444Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, et al.; Childhood Myositis Heterogeneity Study Group. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res (Hoboken). 2017;69(7):1088-1094. doi: 10.1002/acr.23113Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, et al.; Childhood Myositis Heterogeneity Study Group. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res (Hoboken). 2017;69(7):1088-1094. doi: 10.1002/acr.23113Li D, Tansley SL. Juvenile dermatomyositis – Clinical phenotypes. Curr Rheumatol Rep. 2019;21(12):74. doi: 10.1007/s11926-019-0871-4Li D, Tansley SL. Juvenile dermatomyositis – Clinical phenotypes. Curr Rheumatol Rep. 2019;21(12):74. doi: 10.1007/s11926-019-0871-4Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: Significance of early clinical and laboratory features. Arthritis Rheum. 2008;58(11):3585-3592. doi: 10.1002/art.23960Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: Significance of early clinical and laboratory features. Arthritis Rheum. 2008;58(11):3585-3592. doi: 10.1002/art.23960Каледа МИ, Никишина ИП, Салугина СО, Федоров ЕС, Арсеньева СВ, Шаповаленко А.Н., и др. Ювенильные идиопатические воспалительные миопатии: результаты открытого одноцентрового ретроспективного исследования. Современная ревматология. 2022;16(4):32-39. doi: 10.14412/1996-7012-2022-4-32-39Kaleda MI, Nikishina IP, Salugina SO, Fedorov ES, Arsenyeva SV, Shapovalenko AN, et al. Juvenile idiopathic inflammatory myopathies: results of an open single-center retrospective study. Modern Rheumatology Journal. 2022;16(4):32-39 (In Russ.) doi: 10.14412/1996-7012-2022-4-32-39Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006;148(2):247-253. doi: 10.1016/j.jpeds.2005.10.032Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006;148(2):247-253. doi: 10.1016/j.jpeds.2005.10.032Gitiaux C, De Antonio M, Aouizerate J, Gherardi RK, Guilbert T, Barnerias C, Bodemer C, et al. Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis. Rheumatology (Oxford). 2016;55(3):470-479. doi: 10.1093/rheumatology/kev359Gitiaux C, De Antonio M, Aouizerate J, Gherardi RK, Guilbert T, Barnerias C, Bodemer C, et al. Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis. Rheumatology (Oxford). 2016;55(3):470-479. doi: 10.1093/rheumatology/kev359Papadopoulou C, Hong Y, Krol P, Al Obaidi M, Pilkington C, Wedderburn LR, et al. The vasculopathy of juvenile dermatomyositis: Endothelial injury, hypercoagulability, and increased arterial stiffness. Arthritis Rheumatol. 2021;73(7):1253-1266. doi: 10.1002/art.41639Papadopoulou C, Hong Y, Krol P, Al Obaidi M, Pilkington C, Wedderburn LR, et al. The vasculopathy of juvenile dermatomyositis: Endothelial injury, hypercoagulability, and increased arterial stiffness. Arthritis Rheumatol. 2021;73(7):1253-1266. doi: 10.1002/art.41639McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al.; Juvenile Dermatomyositis Research Group. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) – Clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006; 45(10):1255-1260. doi: 10.1093/rheumatology/kel099McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al.; Juvenile Dermatomyositis Research Group. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) – Clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006; 45(10):1255-1260. doi: 10.1093/rheumatology/kel099Sanner H, Aaløkken TM, Gran JT, Sjaastad I, Johansen B, Flatø B. Pulmonary outcome in juvenile dermatomyositis: A case-control study. Ann Rheum Dis. 2011;70(1):86-91. doi: 10.1136/ard.2010.131433Sanner H, Aaløkken TM, Gran JT, Sjaastad I, Johansen B, Flatø B. Pulmonary outcome in juvenile dermatomyositis: A case-control study. Ann Rheum Dis. 2011;70(1):86-91. doi: 10.1136/ard.2010.131433Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF; CARRA Juvenile Myositis subgroup. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: A survey of pediatric rheumatologists by the Childhood Arthritis and Rheumatology Research Alliance (CARRA). Pediatr Rheumatol Online J. 2017;15(1):71. doi: 10.1186/s12969-017-0199-4Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF; CARRA Juvenile Myositis subgroup. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: A survey of pediatric rheumatologists by the Childhood Arthritis and Rheumatology Research Alliance (CARRA). Pediatr Rheumatol Online J. 2017;15(1):71. doi: 10.1186/s12969-017-0199-4Mehta P, Lawrence A, Gupta L, Misra DP, Agarwal V, Misra R, et al. Long-standing and poorly controlled disease in juvenile dermatomyositis is associated with calcinosis: A real-world experience from a low-middle income country. Rheumatol Int. 2023 Jul 5. doi: 10.1007/s00296-023-05377-4Mehta P, Lawrence A, Gupta L, Misra DP, Agarwal V, Misra R, et al. Long-standing and poorly controlled disease in juvenile dermatomyositis is associated with calcinosis: A real-world experience from a low-middle income country. Rheumatol Int. 2023 Jul 5. doi: 10.1007/s00296-023-05377-4Yi BY, Marrs J, Acharya P, Sura A, Cidon M. Risk factors for developing calcinosis in juvenile dermatomyositis: Subcutaneous and myofascial edema in initial magnetic resonance imaging. Rheumatol Int. 2023 Jul 11. doi: 10.1007/s00296-023-05385-4Yi BY, Marrs J, Acharya P, Sura A, Cidon M. Risk factors for developing calcinosis in juvenile dermatomyositis: Subcutaneous and myofascial edema in initial magnetic resonance imaging. Rheumatol Int. 2023 Jul 11. doi: 10.1007/s00296-023-05385-4Okiyama N. Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies. J Clin Med. 2021;10(8):1725. doi: 10.3390/jcm10081725Okiyama N. Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies. J Clin Med. 2021;10(8):1725. doi: 10.3390/jcm10081725Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007;157(4):637-644. doi: 10.1111/j.1365-2133.2007.08055.xGerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007;157(4):637-644. doi: 10.1111/j.1365-2133.2007.08055.xMamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology (Oxford). 2018; 57(11):1956-1963. doi: 10.1093/rheumatology/key190Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology (Oxford). 2018; 57(11):1956-1963. doi: 10.1093/rheumatology/key190Gezgin Yıldırım D, Baglan E, Güngörer V, Yıldız C, Tuncez S, Bülbül M, et al. Comparison of clinical and laboratory features and treatment responses in patients with clinically amyopathic juvenile dermatomyositis and classical juvenile dermatomyositis. Int J Rheum Dis. 2023;26(8):1504-1511. doi: 10.1111/1756-185X.14773Gezgin Yıldırım D, Baglan E, Güngörer V, Yıldız C, Tuncez S, Bülbül M, et al. Comparison of clinical and laboratory features and treatment responses in patients with clinically amyopathic juvenile dermatomyositis and classical juvenile dermatomyositis. Int J Rheum Dis. 2023;26(8):1504-1511. doi: 10.1111/1756-185X.14773Xia J, Jiang G, Jin T, Shen Q, Ma Y, Wang L, et al. Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: A case report with literature review. BMC Pediatr. 2021;21(1):488. doi: 10.1186/s12887-021-02958-9Xia J, Jiang G, Jin T, Shen Q, Ma Y, Wang L, et al. Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: A case report with literature review. BMC Pediatr. 2021;21(1):488. doi: 10.1186/s12887-021-02958-9Kishi T, Tani Y, Okiyama N, Mizuochi K, Ichimura Y, Harigai M, et al. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease – A case report. Pediatr Rheumatol Online J. 2021;19(1):34. doi: 10.1186/s12969-021-00532-2Kishi T, Tani Y, Okiyama N, Mizuochi K, Ichimura Y, Harigai M, et al. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease – A case report. Pediatr Rheumatol Online J. 2021;19(1):34. doi: 10.1186/s12969-021-00532-2Abu-Rumeileh S, Marrani E, Maniscalco V, Maccora I, Pagnini I, Mastrolia MV, et al. Lung involvement in juvenile idiopathic inflammatory myopathy: A systematic review. Autoimmun Rev. 2023;22(10):103416. doi: 10.1016/j.autrev.2023.103416Abu-Rumeileh S, Marrani E, Maniscalco V, Maccora I, Pagnini I, Mastrolia MV, et al. Lung involvement in juvenile idiopathic inflammatory myopathy: A systematic review. Autoimmun Rev. 2023;22(10):103416. doi: 10.1016/j.autrev.2023.103416Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al.; Childhood Myositis Heterogeneity Collaborative Study Group. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223-243. doi: 10.1097/MD.0b013e31829d08f9Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al.; Childhood Myositis Heterogeneity Collaborative Study Group. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223-243. doi: 10.1097/MD.0b013e31829d08f9Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20(4): 21. doi: 10.1007/s11926-018-0732-6Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20(4): 21. doi: 10.1007/s11926-018-0732-6Binns EL, Moraitis E, Maillard S, Tansley S, McHugh N, Jacques TS, et al.; UK Juvenile Dermatomyositis Research Group (UK and Ireland). Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature. Pediatr Rheumatol Online J. 2017;15(1):77. doi: 10.1186/s12969-017-0205-xBinns EL, Moraitis E, Maillard S, Tansley S, McHugh N, Jacques TS, et al.; UK Juvenile Dermatomyositis Research Group (UK and Ireland). Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature. Pediatr Rheumatol Online J. 2017;15(1):77. doi: 10.1186/s12969-017-0205-xWedderburn LR, McHugh NJ, Chinoy H, Cooper RG, Salway F, Ollier WE, et al.; Juvenile Dermatomyositis Research Group (JDRG). HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford). 2007;46(12):1786-1791. doi: 10.1093/rheumatology/kem265Wedderburn LR, McHugh NJ, Chinoy H, Cooper RG, Salway F, Ollier WE, et al.; Juvenile Dermatomyositis Research Group (JDRG). HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford). 2007;46(12):1786-1791. doi: 10.1093/rheumatology/kem265Bitencourt N, Solow EB, Wright T, Bermas BL. Inflammatory myositis in systemic lupus erythematosus. Lupus. 2020;29(7):776-781. doi: 10.1177/0961203320918021Bitencourt N, Solow EB, Wright T, Bermas BL. Inflammatory myositis in systemic lupus erythematosus. Lupus. 2020;29(7):776-781. doi: 10.1177/0961203320918021Martin N, Krol P, Smith S, Murray K, Pilkington CA, Davidson JE, et al.; Juvenile Dermatomyositis Research Group. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years’ experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford). 2011;50(1):137-145. doi: 10.1093/rheumatology/keq261Martin N, Krol P, Smith S, Murray K, Pilkington CA, Davidson JE, et al.; Juvenile Dermatomyositis Research Group. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years’ experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford). 2011;50(1):137-145. doi: 10.1093/rheumatology/keq261Moneta GM, Pires Marafon D, Marasco E, Rosina S, Verardo M, Fiorillo C, et al. Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features. Arthritis Rheumatol. 2019;71(6):1011-1021. doi: 10.1002/art.40800Moneta GM, Pires Marafon D, Marasco E, Rosina S, Verardo M, Fiorillo C, et al. Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features. Arthritis Rheumatol. 2019;71(6):1011-1021. doi: 10.1002/art.40800Wilkinson MGL, Radziszewska A, Wincup C, Ioannou Y, Isenberg DA, Manson JJ, et al. Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. Rheumatology (Oxford). 2020;59(1):194-204. doi: 10.1093/rheumatology/kez252Wilkinson MGL, Radziszewska A, Wincup C, Ioannou Y, Isenberg DA, Manson JJ, et al. Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. Rheumatology (Oxford). 2020;59(1):194-204. doi: 10.1093/rheumatology/kez252Piper CJM, Wilkinson MGL, Deakin CT, Otto GW, Dowle S, Duurland CL, et al. CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through Toll-like receptor 7 and interferon-α. Front Immunol. 2018;9:1372. doi: 10.3389/fimmu.2018.01372Piper CJM, Wilkinson MGL, Deakin CT, Otto GW, Dowle S, Duurland CL, et al. CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through Toll-like receptor 7 and interferon-α. Front Immunol. 2018;9:1372. doi: 10.3389/fimmu.2018.01372Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403-407.Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403-407.Brown VE, Pilkington CA, Feldman BM, Davidson JE; Network for juvenile dermatomyositis, Paediatric Rheumatology European Society (PReS). An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006;45(8):990-993. doi: 10.1093/rheumatology/kel025Brown VE, Pilkington CA, Feldman BM, Davidson JE; Network for juvenile dermatomyositis, Paediatric Rheumatology European Society (PReS). An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006;45(8):990-993. doi: 10.1093/rheumatology/kel025Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al.; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271-2282. doi: 10.1002/art.40320Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al.; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271-2282. doi: 10.1002/art.40320Patel B, Khan N, Werth VP. Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease. J Am Acad Dermatol. 2018;79(1):77-83.e1. doi: 10.1016/j.jaad.2017.12.055Patel B, Khan N, Werth VP. Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease. J Am Acad Dermatol. 2018;79(1):77-83.e1. doi: 10.1016/j.jaad.2017.12.055Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329-340. doi: 10.1136/annrheumdis-2016-209247Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329-340. doi: 10.1136/annrheumdis-2016-209247Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/ Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBM-FRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S118-S157. doi: 10.1002/acr.20532Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/ Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBM-FRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S118-S157. doi: 10.1002/acr.20532Gebreamlak A, Sawicka KM, Garrett R, Goh YI, Baker KM, Feldman BM. Currently recommended skin scores correlate highly in the assessment of patients with juvenile dermatomyositis (JDM). Pediatr Rheumatol Online J. 2023;21(1):63. doi: 10.1186/s12969-023-00844-5Gebreamlak A, Sawicka KM, Garrett R, Goh YI, Baker KM, Feldman BM. Currently recommended skin scores correlate highly in the assessment of patients with juvenile dermatomyositis (JDM). Pediatr Rheumatol Online J. 2023;21(1):63. doi: 10.1186/s12969-023-00844-5Gargh K, Al-Abadi E, Low S, Harrison K, Coles W, Davis P, et al. Juvenile Dermatomyositis Magnetic Resonance Imaging Score (JIS) does not correlate with criteria for clinically inactive disease: A single-centre retrospective evaluation. Rheumatol Int. 2022;42(7):1221-1226. doi: 10.1007/s00296-021-05049-1Gargh K, Al-Abadi E, Low S, Harrison K, Coles W, Davis P, et al. Juvenile Dermatomyositis Magnetic Resonance Imaging Score (JIS) does not correlate with criteria for clinically inactive disease: A single-centre retrospective evaluation. Rheumatol Int. 2022;42(7):1221-1226. doi: 10.1007/s00296-021-05049-1Kobayashi I, Akioka S, Kobayashi N, Iwata N, Takezaki S, Nakaseko H, et al. Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. Mod Rheumatol. 2020;30(3):411-423. doi: 10.1080/14397595.2020.1718866Kobayashi I, Akioka S, Kobayashi N, Iwata N, Takezaki S, Nakaseko H, et al. Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. Mod Rheumatol. 2020;30(3):411-423. doi: 10.1080/14397595.2020.1718866Хелковская-Сергеева АН, Ананьева ЛП, Казаков ДО, Насонов ЕЛ. Применение магнитно-резонансной томографии в диагностике идиопатических воспалительных миопатий. Современная ревматология. 2019;13(1):95-100. doi: 10.14412/1996-7012-2019-1-95-100Khelkovskaya-Sergeeva AN, Ananyeva LP, Kazakov DO, Nasonov EL. Use of magnetic resonance imaging in the diagnosis of idiopathic inflammatory myopathies. Modern Rheumatology Journal. 2019;13(1):95-100 (In Russ.)]. doi: 10.14412/1996-7012-2019-1-95-100Gao W, Yuan C, Zou Y, Lin H. Development and pilot testing a self-reported pediatric PROMIS app for young children aged 5–7 years. J Pediatr Nurs. 2020;53:74-83. doi: 10.1016/j.pedn.2020.04.003Gao W, Yuan C, Zou Y, Lin H. Development and pilot testing a self-reported pediatric PROMIS app for young children aged 5–7 years. J Pediatr Nurs. 2020;53:74-83. doi: 10.1016/j.pedn.2020.04.003Patel REV, Lai J-S, Gray E, Chang R, Cella D, Ardalan K. Comparison of PROMIS computerized adaptive testing administered item banks vs fixed short forms in juvenil myositis. Arthritis Rheum. 2019;71(10):abstract #433.Patel REV, Lai J-S, Gray E, Chang R, Cella D, Ardalan K. Comparison of PROMIS computerized adaptive testing administered item banks vs fixed short forms in juvenil myositis. Arthritis Rheum. 2019;71(10):abstract #433.Li YR, Li J, Zhao SD, Bradfield JP, Mentch FD, Maggadottir SM, et al. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nat Med. 2015;21(9):1018-1027. doi: 10.1038/nm.3933Li YR, Li J, Zhao SD, Bradfield JP, Mentch FD, Maggadottir SM, et al. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nat Med. 2015;21(9):1018-1027. doi: 10.1038/nm.3933Molano-González N, Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Rodríguez Y, et al. Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J Autoimmun. 2019;98:24-32. doi: 10.1016/j.jaut.2018.11.002Molano-González N, Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Rodríguez Y, et al. Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J Autoimmun. 2019;98:24-32. doi: 10.1016/j.jaut.2018.11.002Malagón C, Gomez MDP, Mosquera C, Vargas C, Gonzalez T, Arango C, et al. Juvenile polyautoimmunity in a rheumatology setting. Autoimmun Rev. 2019;18(4):369-381. doi: 10.1016/j.autrev.2018.11.006Malagón C, Gomez MDP, Mosquera C, Vargas C, Gonzalez T, Arango C, et al. Juvenile polyautoimmunity in a rheumatology setting. Autoimmun Rev. 2019;18(4):369-381. doi: 10.1016/j.autrev.2018.11.006Anaya JM, Rojas-Villarraga A, Mantilla RD, Arcos-Burgos M, Sarmiento-Monroy JC. Polyautoimmunity in Sjögren syndrome. Rheum Dis Clin North Am. 2016;42(3):457-472. doi: 10.1016/j.rdc.2016.03.005Anaya JM, Rojas-Villarraga A, Mantilla RD, Arcos-Burgos M, Sarmiento-Monroy JC. Polyautoimmunity in Sjögren syndrome. Rheum Dis Clin North Am. 2016;42(3):457-472. doi: 10.1016/j.rdc.2016.03.005Каледа МИ, Никишина ИП, Латыпова АН. Синдром Шегрена с дебютом в детском возрасте. Терапевтический архив. 2019; 91(5):54-60. [Kaleda MI, Nikishina IP, Latypova AN. Sjögren’s syndrome with juvenile onset. Terapevticheskii arkhiv. 2019; 91(5):54-60 (In Russ.)]. doi: 10.26442/00403660.2019.05.000189Kaleda MI, Nikishina IP, Latypova AN. Sjögren’s syndrome with juvenile onset. Terapevticheskii arkhiv. 2019; 91(5):54-60 (In Russ.)]. doi: 10.26442/00403660.2019.05.000189Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: The SHARE initiative. Ann Rheum Dis. 2017;76(12):1965-1973. doi: 10.1136/annrheumdis-2017-211898Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: The SHARE initiative. Ann Rheum Dis. 2017;76(12):1965-1973. doi: 10.1136/annrheumdis-2017-211898Ramaswamy M, Tummala R, Streicher K, Nogueira da Costa A, Brohawn PZ. The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases. Int J Mol Sci. 2021;22(20):11286. doi: 10.3390/ijms222011286Ramaswamy M, Tummala R, Streicher K, Nogueira da Costa A, Brohawn PZ. The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases. Int J Mol Sci. 2021;22(20):11286. doi: 10.3390/ijms222011286Насонов ЕЛ, Решетняк ТМ, Соловьев СК, Попкова ТВ. Системная красная волчанка и антифосфолипидный синдром: вчера, сегодня, завтра. Терапевтический архив. 2023; 95(5):365-374. doi: 10.26442/00403660.2023.05.202246Nasonov EL, Reshetnyak TM, Solovyev SK, Popkova TV. Systemic lupus erythematosus and antiphospholipid syndrome: Past, present, future. Terapevticheskii arkhiv. 2023;95(5): 365-337 (In Russ.). doi: 10.26442/00403660.2023.05.202246Jansson AF, Sengler C, Kuemmerle-Deschner J, Gruhn B, Kranz AB, Lehmann H, et al. B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol. 2011;30(1):87-97. doi: 10.1007/s10067-010-1630-0Jansson AF, Sengler C, Kuemmerle-Deschner J, Gruhn B, Kranz AB, Lehmann H, et al. B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol. 2011;30(1):87-97. doi: 10.1007/s10067-010-1630-0Werner A, Schäfer S, Zaytseva O, Albert H, Lux A, Krištić J, et al. Targeting B cells in the pre-phase of systemic autoimmunity globally interferes with autoimmune pathology. iScience. 2021;24(9):103076. doi: 10.1016/j.isci.2021.103076Werner A, Schäfer S, Zaytseva O, Albert H, Lux A, Krištić J, et al. Targeting B cells in the pre-phase of systemic autoimmunity globally interferes with autoimmune pathology. iScience. 2021;24(9):103076. doi: 10.1016/j.isci.2021.103076Merino-Vico A, Frazzei G, van Hamburg JP, Tas SW. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches. Eur J Immunol. 2023;53(1):e2149675. doi: 10.1002/eji.202149675Merino-Vico A, Frazzei G, van Hamburg JP, Tas SW. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches. Eur J Immunol. 2023;53(1):e2149675. doi: 10.1002/eji.202149675Welzel T, Winskill C, Zhang N, Woerner A, Pfister M. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – What we know and what we do not know from randomized controlled trials. Pediatr Rheumatol Online J. 2021;19(1):46. doi: 10.1186/s12969-021-00514-4Welzel T, Winskill C, Zhang N, Woerner A, Pfister M. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – What we know and what we do not know from randomized controlled trials. Pediatr Rheumatol Online J. 2021;19(1):46. doi: 10.1186/s12969-021-00514-4Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. doi: 10.14412/1995-4484-2019-3-40Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57:1-40 (In Russ.). doi: 10.14412/1995-4484-2019-3-40Mahmoud I, Jellouli M, Boukhris I, Charfi R, Ben Tekaya A, Saidane O, et al. Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: A systematic review. J Pediatr. 2017;187:213-219.e2. doi: 10.1016/j.jpeds.2017.05.002Mahmoud I, Jellouli M, Boukhris I, Charfi R, Ben Tekaya A, Saidane O, et al. Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: A systematic review. J Pediatr. 2017;187:213-219.e2. doi: 10.1016/j.jpeds.2017.05.002Sawhney S, Agarwal M. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. Lupus. 2021;30(11):1829-1836. doi: 10.1177/09612033211034567Sawhney S, Agarwal M. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. Lupus. 2021;30(11):1829-1836. doi: 10.1177/09612033211034567Zulian F, Dal Pozzolo R, Meneghel A, Castaldi B, Marcolongo R, Caforio ALP, et al. Rituximab for rapidly progressive juvenile systemic sclerosis. Rheumatology (Oxford). 2020;59(12):3793-3797. doi: 10.1093/rheumatology/keaa193Zulian F, Dal Pozzolo R, Meneghel A, Castaldi B, Marcolongo R, Caforio ALP, et al. Rituximab for rapidly progressive juvenile systemic sclerosis. Rheumatology (Oxford). 2020;59(12):3793-3797. doi: 10.1093/rheumatology/keaa193Marrani E, Abu-Rumeileh S, Mastrolia MV, Maccora I, Pagnini I, Simonini G. A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: An evidence gap in precision medicine. Clin Exp Rheumatol. 2022;40(2):457-470. doi: 10.55563/clinexprheumatol/ltrj4lMarrani E, Abu-Rumeileh S, Mastrolia MV, Maccora I, Pagnini I, Simonini G. A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: An evidence gap in precision medicine. Clin Exp Rheumatol. 2022;40(2):457-470. doi: 10.55563/clinexprheumatol/ltrj4lКаледа МИ, Никишина ИП, Николаева ЕВ, Шаповаленко АН, Федоров ЕС, Пачкория ТН. Ритуксимаб при ревматических заболеваниях у детей: результаты ретроспективного исследования безопасности терапии. Научно-практическая ревматология. 2021;59(2):208-214. doi: 10.47360/1995-4484-2021-208-214Kaleda MI, Nikishina IP, Nikolaeva EV, Shapovalenko AN, Fedorov ES, Pachkoria TN. Rituximab for rheumatic diseases in children: Results of a retrospective study of the safety of therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2):208-214 (In Russ.)]. doi: 10.47360/1995-4484-2021-208-214Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi: 10.47360/1995-4484-2021-367-383Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367-383 (In Russ.). doi: 10.47360/1995-4484-2021-367-383Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340-1348. doi: 10.1136/annrheumdis-2020-217101Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340-1348. doi: 10.1136/annrheumdis-2020-217101Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, et al.; Abatacept in Dermatomyositis (AID) Trial Investigators. Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy. Arthritis Rheumatol. 2023;75(7):1229-1237. doi: 10.1002/art.42450Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, et al.; Abatacept in Dermatomyositis (AID) Trial Investigators. Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy. Arthritis Rheumatol. 2023;75(7):1229-1237. doi: 10.1002/art.42450Kalampokis I, Yi BY, Smidt AC. Abatacept in the treatment of localized scleroderma: A pediatric case series and systematic literature review. Semin Arthritis Rheum. 2020;50(4):645-656. doi: 10.1016/j.semarthrit.2020.03.020Kalampokis I, Yi BY, Smidt AC. Abatacept in the treatment of localized scleroderma: A pediatric case series and systematic literature review. Semin Arthritis Rheum. 2020;50(4):645-656. doi: 10.1016/j.semarthrit.2020.03.020Adrovic A, Yildiz M, Haslak F, Koker O, Aliyeva A, Sahin S, et al. Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study. Rheumatol Int. 2021;41(1):121-128. doi: 10.1007/s00296-020-04732-zAdrovic A, Yildiz M, Haslak F, Koker O, Aliyeva A, Sahin S, et al. Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study. Rheumatol Int. 2021;41(1):121-128. doi: 10.1007/s00296-020-04732-zPin A, Tesser A, Pastore S, Moressa V, Valencic E, Arbo A, et al. Biological and clinical changes in a pediatric series treated with off-label JAK inhibitors. Int J Mol Sci. 2020;21(20):7767. doi: 10.3390/ijms21207767Pin A, Tesser A, Pastore S, Moressa V, Valencic E, Arbo A, et al. Biological and clinical changes in a pediatric series treated with off-label JAK inhibitors. Int J Mol Sci. 2020;21(20):7767. doi: 10.3390/ijms21207767Chuprin J, McCormack L, Richmond JM, Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: An update. Expert Rev Clin Immunol. 2022;18(3):263-272. doi: 10.1080/1744666X.2022.2047022Chuprin J, McCormack L, Richmond JM, Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: An update. Expert Rev Clin Immunol. 2022;18(3):263-272. doi: 10.1080/1744666X.2022.2047022

The authors declare that there are no conflicts of interest present.